| Offering Information |
| Expected Date | WITHDRAWN |
| Proposed Exchange/Ticker |
-: EPCT |
| Security Type |
Common Stock |
| Lead Underwriter |
Wachovia Securities Inc |
| Days In Registration |
129 |
| Date Filed |
10-Jan-2005 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2008) |
| Industry |
Manufacturing |
| Business Description |
EpiCept Corp, located in Tarrytown, New York, manufactures pharmaceuticals, focused on the development and commercialization of topically-delivered prescription pain management therapeutics. Its lead product is Ceplene(R), which when used concomitantly with interleukin-2 or IL-2, is intended as remission maintenance therapy in the treatment of acute myeloid leukemia or AML for adult patients who are in their first complete remission. The company was incorporated in 1993. |
| Revenue |
- |
| Net Income |
- |
| Shares Outstanding (post-offering) |
17.39M |
| Contact |
- |
| Number of Employees |
21 |
|
| Original Filing Information |
| US |
| Shares Filed |
5.5M |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
- |
| · As a Percent |
- |
| Overallotment Shares Filed |
825.0K |
| File Amount |
- |
| File Price Range |
$13.00 - $11.00 |
| File Mid Price |
$12.00 |
|
